Janssen-Cilag
| Janssen-Cilag GmbH
|
|
|---|---|
 |
|
| legal form | GmbH |
| founding | 1959 |
| Seat | Neuss |
| management | Chairman of the Supervisory Board: Karen Puck, Management: Andreas Gerber (Chairman), Peter Solberg, Dr. Christoph Bug |
| Number of employees | approx. 1,000 |
| sales | 1.43 billion (2018) |
| Website | www.janssen.com/germany |
The Janssen-Cilag GmbH is a research-based pharmaceutical company based in Neuss . The company employs around 1,000 people across Germany and generated sales of 1.43 billion euros in 2018. Janssen is part of the international healthcare group Johnson & Johnson . The founder and namesake of the company is the Belgian researcher and chemist Dr. Paul Janssen.
history
The company was founded in 1936 as Cilag Chemie by the chemist Bernhard Joos in Schaffhausen (Switzerland). In 1952 a German branch was established. In 1953, the chemist and doctor Paul Janssen founded Janssen Pharmaceutica NV in Turnhout (Belgium). In the same year, the American healthcare group Johnson & Johnson took over Cilag Chemie. In 1961, Johnson & Johnson also acquired the drug manufacturer Janssen.
In 1980 the company headquarters was relocated from Janssen Germany to Neuss. In 1996, Cilag Chemie and Janssen merged to form today's Janssen-Cilag GmbH.
In 2017, the biopharmaceutical company Actelion was acquired by the Janssen Pharmaceutical Companies of Johnson & Johnson and thus part of the global healthcare group. At the beginning of 2020, Actelion Pharmaceuticals Deutschland GmbH merged with Janssen-Cilag GmbH and will be integrated as the "Pulmonary Hypertension" therapeutic area.
research
The fields of activity of Janssen are oncology ( anemia in cancer , multiple myeloma , prostate cancer , breast cancer , ovarian cancer , acute myeloid leukemia , chronic lymphocytic leukemia , mantle cell lymphoma), immunology ( psoriasis , psoriatic arthritis , rheumatoid arthritis and Crohn's disease ), neurology / psychiatry ( ADHD , Epilepsy , schizophrenia , pain), infectious diseases (e.g. HIV / AIDS , tuberculosis ), as well as pulmonary hypertension / pulmonary arterial hypertension.
Janssen is currently researching the possibilities of the Disease Interception concept. With this approach, the company wants to develop ways to stop diseases before they arise. The concept differs from classic prevention: while prevention aims at the early detection of symptoms, disease interception is to be used to identify diseases and prevent their onset before the first symptoms can appear. Janssen advocates a society-wide debate about the ethical and health-political effects of disease interception and is currently researching ways of realizing the approach in a World Without Disease Accelerator. Janssen is currently researching, among other things, the use of disease interception in smoldering myeloma, type 1 diabetes and Alzheimer's disease . 18 of the active ingredients developed by Janssen are on the list of indispensable drugs of the World Health Organization (WHO ).
Janssen is a member of the Association of Research Drug Manufacturers. V.
See also
Web links
- www.janssen.com/germany
- www.janssenmedicalcloud.de (specialist groups)
Individual evidence
- ↑ Data and facts
- ↑ a b c company profile. Retrieved April 14, 2020 .
- ^ Janssen-Cilag GmbH, Neuss. Retrieved April 14, 2020 .
- ^ Johnson & Johnson in Germany: Pharmaceuticals. Retrieved April 14, 2020 .
- ↑ Monitor Health Services Research. Retrieved April 14, 2020 .
- ^ World Without Disease Accelerator. Retrieved April 14, 2020 .
- ↑ WHO. Retrieved April 14, 2020 (English).